BIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exits
The final day of BIO delivered insights on early stage investment strategy from Lilly and Boehringer Ingelheim, the best type of biotech M&A, and another debate over terminology at the US FDA - this time on "ultra-rare."
Scrip - June 25, 2026

Remix Takes RNA-Modulation Approach Public Through Merger With Passage Bio
Merger brings cancer-focused Remix public and will coincide with a $100m private placement. Passage’s demise is the latest setback in the gene therapy space.
Scrip - June 25, 2026

Otsuka Posts Positive Phase IIIb Results For Centanafadine Just Ahead Of PDUFA Date
The company said the trial met the primary and key secondary endpoints, though the market for ADHD generally and non-stimulant drugs particularly is highly competitive.
Scrip - June 25, 2026

Executives On The Move: Paulo Fontoura To Joining Sanofi And Spearhead Pharma R&D
Other recent moves in the industry include changes at the top at Spruce Biosciences and Adial Pharmaceuticals, plus internal moves at Bristol Myers Squibb and Pfizer.
Scrip - June 25, 2026

Pfizer’s Ibrance Snags Double-Positive Approval As Patent Cliff Looms
US FDA approval for Ibrance in "double-positive" breast cancer comes just ahead of its 2027 US patent cliff.
Scrip - June 25, 2026

Europe Must Invest To Stay Globally Relevant, Says Biopharma VC Leader
Forbion’s Sander Slootweg is leading a call for greater investment in venture capital and private equity funds to help Europe compete with the US and China in key technologies.
Scrip - June 25, 2026

China Claudin 18.2 ADCs Enter Final Stretch Of Global Race With NDAs
As of June, Chinese firms Innovent and Sino Biopharmaceutical had filed new drug applications in China for their Claudin 18.2-targeting contenders IBI343 and LM-302 in third-line gastric or gastroesophageal junction cancer.
Scrip - June 25, 2026

BIO Notebook: A Post-Mortem On The CNPV
The third day of BIO featured a debate over the origins and future of the CNPV, reflections on dealmaking strategies, and how neuroinflammation is a growing path for Alzheimer's research.
Scrip - June 25, 2026

Whoop Back In The Loop. FDA Closes Out July Warning Letter Over Company’s Blood Pressure Product
The US FDA has closed out its warning letter from July 2025 against wearables maker Whoop. The FDA initially determined Whoop’s blood pressure monitoring product was a diagnostic tool, not a wellness product. Now, the FDA’s stance aligns more with wellness guidance the agency issued in January.
Medtech Insight - June 25, 2026

AI Coach, Meal Photos: Dexcom Rebuilds Stelo From The Ground Up, Takes It Global
Dexcom is relaunching Stelo in everything but name — a rebuilt app with AI coaching, meal photo logging, and pattern recognition, plus FDA clearance for children as young as two and expansion into four new international markets, all arriving within months of each other.
Medtech Insight - June 25, 2026

Adhesives Giant H.B. Fuller Pushes Into Surgical Devices With £715m AMS Buy
The US adhesives maker has agreed an all-cash takeover of £715m ($942.9m) for the UK Advanced Medical Solutions at 285p a share — a 35% premium — pushing deeper into higher-margin medical markets and expanding its addressable market by $15bn.
Medtech Insight - June 25, 2026

EU Set To Beat 2030 Target For EHR Access
Belgium and Estonia highlighted as e-Health success stories while Ireland falls behind.
Medtech Insight - June 25, 2026

US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news: Trump urges helping hemp industry; DEA marijuana scheduling hearing set; TEA OTC pathway end planned; FDA’s “Real Cost” tobacco prevention campaigns results; OMUFA arrears list grows; more.
HBW Insight - June 26, 2026

States Lose Pfizer As US Generics Cartel Case Shrinks
Pfizer has been dismissed from US states’ sprawling generics price-fixing case, while leaving its former Greenstone authorized generic unit exposed on several individual-drug claims.
Generics Bulletin - June 25, 2026

Xspray’s Launch-Ready Nilotinib Hits FDA Roadblock
Xspray’s FDA setback for Nilopki complicates its near-term US launch plans, adding product-specific dose and manufacturing questions to the already-known facility inspection overhang.
Generics Bulletin - June 25, 2026

‘It’s Important That We Evolve’ – IGBA’s Gaunt On Being The Voice Of The Global Off-Patent Industry
Ana Gaunt recently took over as secretary general of the IGBA. Talking to Generics Bulletin, she sets out her four key priority areas, while also revealing future initiatives – including a value-based report as well as refocusing certain IGBA activities to give member associations a stronger voice.
Generics Bulletin - June 25, 2026

Automating Clinical Decisions For Healthcare System Efficiencies
AI-enabled workflow-centric approaches are gaining currency as health systems and life science innovators see potential to slash administrative bloat, accelerate clinical trials and optimize clinical operations. But there remains a chasm between AI healthcare promises and clinical reality.
In Vivo - June 26, 2026